Skip to Content

Syneos Health Inc Class A SYNH Stock Quote

| Rating as of

Morningstar‘s Stock Analysis SYNH

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Narrow-Moat Syneos’ Strong Backlog Supports Continued Growth; Shares Fairly Valued

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

INC Research’s 2017 merger with inVentiv Health launched Syneos Health, the new entity, into the upper echelon of large global late-stage contract research organizations, but at the price of a significant debt load. We believe Syneos is one of a handful of CROs with the global infrastructure necessary to compete for large multinational late-stage trials and secure strategic partnerships with large pharmaceutical companies. However, its debt load could limit capital deployment in the near term.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics SYNH

Company Profile SYNH

Business Description

Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company’s commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

1030 Sync Street
Morrisville, NC, 27560-5468
T +1 919 876-9300
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 27,525